Miniatura

Fitxers

soy2015_1847.pdf (167.13 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2015-03-30

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/99515

Population pharmacokinetics of benznidazole in adult patients with Chagas disease

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1128/AAC.05018-14

Resum

AIM: To build a population pharmacokinetic (PopPK) model to characterize benznidazole (BNZ) pharmacokinetics in adults with chronic Chagas disease. METHODS: Prospective, open-label, single-center clinical trial(EudraCT:2011-002900-34;CINEBENZclinicaltrials.govnumber:NCT01755403), approved by the local ethics committee. Patients received 2.5mg/kg/12h (Abarax(R), Elea Laboratory, Argentina) for 60 days. Plasma BZN samples were taken at several times along the study and analyzed by HPLC-UV. The PopPK analysis was done with NONMEMv.7.3. Demographic and biological data were tested as covariates. Intraindividual, interoccasion and residual variability were modeled. Internal and external validations were completed to assess the robustness of the model. Later on, simulations were performed to generate the BNZ concentration-time course profile for different dosage regimens. RESULTS: A total of 358 plasma BZN concentrations from 39 patients were included in the analysis. A one-compartment-PK-model characterized by clearance(CL/F) and apparent volume of distribution(V/F) with first order absorption(Ka) and elimination, adequately described the data (CL/F:1.73 L/h; V/F:89.6 L; Ka:1.15 h-1). No covariates were found to be significant for CL/F and V/F. Internal and external validation of the final model showed adequate results. Data from simulations revealed that a dose of 2.5mg/kg/12h might lead to overexposure in the most of the patients. A lower dose (2.5mg/kg/24h) was able to achieve trough BNZ plasma concentrations within the accepted therapeutic range of 3-6 mg/L. CONCLUSION: A population PK model for BNZ in adults with chronic Chagas disease has been developed. Dosing simulations showed that a BNZ dose of 2.5 mg/kg/24h would adequately keep BNZ trough plasma concentrations within the recommended target range concentrations for the majority of patients.

Matèries

Malaltia de Chagas, Malalties parasitàries

Matèries (anglès)

Chagas' disease, Parasitic diseases

Citació

Col·leccions

Articles publicats en revistes (ISGlobal)

Citació

SOY MUNER, Dolors, ALDASORO, Edelweiss, GUERRERO, L., POSADA, Elizabeth, SERRET, N., MEJÍA, T., URBINA, Julio a., GASCÓN I BRUSTENGA, Joaquim. Population pharmacokinetics of benznidazole in adult patients
                with Chagas disease. _Antimicrobial Agents and Chemotherapy_. 2015. Vol. 59, núm. 6, pàgs. 3342-3349. [consulta: 15 de gener de 2026]. ISSN: 0066-4804. [Disponible a: https://hdl.handle.net/2445/99515]

Exportar metadades

JSON - METS

Compartir registre